. Author manuscript; available in PMC: 2019 Aug 30.

Published in final edited form as: Biol Blood Marrow Transplant. 2016 Dec 19;23(3):405–411. doi: 10.1016/j.bbmt.2016.12.624

Table 2.

Clinical Outcomes: Daclizumab Therapy Compared with Placebo^*

Outcome	Therapy	HR (95% CI)	P versus Placebo
Overall mortality	Placebo	1.0
	Daclizumab	0.89 (0.61–1.29)	.53
Relapse	Placebo	1.0
	Daclizumab	0.57 (0.32–1.00)	.05
Nonrelapse mortality	Placebo	1.0
	Daclizumab	1.00 (0.63–1.59)	.99
Grade II-IV GVHD	Placebo	1.0
	Daclizumab	1.22 (0.75–1.98)	.42
Chronic GVHD	Placebo	1.0
	Daclizumab	1.49(1.00–2.31)	.08

GVHD indicates graft-versus-host disease; HR, hazard ratio; CI, confidence interval.

A total of 209 patients contributed data to these outcome analyses.